Literature DB >> 30658730

Fibrosis and alcohol-related liver disease.

Carolin Lackner1, Dina Tiniakos2.   

Abstract

Histological fibrosis stage is one of the most important prognostic factors in compensated and decompensated alcohol-related liver disease (ALD). Morphological assessment of fibrosis is useful for patient stratification, enabling individualised management, and for evaluation of treatment effects in clinical studies. In contrast to most chronic liver diseases where fibrosis is portal-based, fatty liver disease (FLD) of alcoholic or non-alcoholic aetiology (NAFLD) is associated with a centrilobular pattern of injury which leads to perivenular fibrosis and/or pericellular fibrosis. Progression of FLD drives expansive pericellular fibrosis, linking vascular structures and paving the way for the development of cirrhosis. At the cirrhotic stage, ongoing tissue damage leads to increasing fibrosis severity due to parenchymal loss and proliferation of fibrous scars. Histologic fibrosis staging systems have been devised, based on topography and the extent of fibrosis, for most chronic liver diseases. The utility of histological staging is reflected in different risks associated with individual fibrosis stages which cannot be reliably distinguished by non-invasive fibrosis assessment. In contrast to NAFLD, ALD-specific staging systems that enable the standardised prognostication required for clinical management and trials are lacking. Although morphological similarities between NAFLD and ALD exist, differences in clinical and histological features may substantially limit the utility of established NAFLD-specific staging systems for prognostication in ALD. This review summarises morphological features of fibrosis in ALD and compares them to other chronic liver diseases, particularly NAFLD. ALD-related fibrosis is examined in the context of pathogenetic mechanisms of fibrosis progression, regression and clinical settings that need to be considered in future prognostically relevant ALD staging approaches.
Copyright © 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alcohol-related liver disease; Fibrosis; Histological staging; Non-alcoholic fatty liver disease; Pathogenesis; Regression

Mesh:

Substances:

Year:  2019        PMID: 30658730     DOI: 10.1016/j.jhep.2018.12.003

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  36 in total

Review 1.  Cellular and molecular basis of liver regeneration.

Authors:  Sushant Bangru; Auinash Kalsotra
Journal:  Semin Cell Dev Biol       Date:  2020-01-22       Impact factor: 7.727

2.  Current Management and Future Treatment of Alcoholic Hepatitis.

Authors:  Mack C Mitchell; Thomas Kerr; H Franklin Herlong
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-04

3.  Epidemiological Realities of Alcoholic Liver Disease: Global Burden, Research Trends, and Therapeutic Promise.

Authors:  Jia Xiao; Fei Wang; Nai-Kei Wong; Yi Lv; Yingxia Liu; Jiajun Zhong; Shuaiyin Chen; Wei Li; Kazuo Koike; Xiaowei Liu; Hua Wang
Journal:  Gene Expr       Date:  2020-07-20

4.  Alcohol-related liver disease: Time for action.

Authors:  Ramon Bataller; Gavin E Arteel; Christophe Moreno; Vijay Shah
Journal:  J Hepatol       Date:  2019-02       Impact factor: 25.083

5.  Second-harmonic generation (SHG) microscopy and hepatic venous pressure gradient-based validation of a novel histological staging system for alcoholic hepatitis.

Authors:  Archana Rastogi; Nayana Patil; Rakhi Maiwall; Chhagan Bihari; Ananda Soshee; Shiv K Sarin
Journal:  Virchows Arch       Date:  2021-04-02       Impact factor: 4.064

Review 6.  The Beneficial Effects of Natural Extracts and Bioactive Compounds on the Gut-Liver Axis: A Promising Intervention for Alcoholic Liver Disease.

Authors:  Liang Zhao; Shaoxuan Wang; Nanhai Zhang; Jingxuan Zhou; Arshad Mehmood; Rifat Nowshin Raka; Feng Zhou; Lei Zhao
Journal:  Antioxidants (Basel)       Date:  2022-06-20

7.  Histologic parameter score does not predict short-term survival in severe alcoholic hepatitis.

Authors:  Margaux Dubois; Amedeo Sciarra; Eric Trépo; Astrid Marot; Joan Saldarriaga; Christophe Moreno; Christine Sempoux; Pierre Deltenre
Journal:  United European Gastroenterol J       Date:  2020-08-10       Impact factor: 4.623

Review 8.  Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification.

Authors:  Saranya Chidambaranathan-Reghupaty; Paul B Fisher; Devanand Sarkar
Journal:  Adv Cancer Res       Date:  2020-11-28       Impact factor: 6.242

Review 9.  Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives.

Authors:  Szu-Yi Liu; I-Ting Tsai; Yin-Chou Hsu
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

10.  Letter to the Editor: Autoimmune Hepatitis and Coronavirus Disease 2019: Disease Outcomes and Tacrolimus Use.

Authors:  Alexander Clevewood Ng
Journal:  Hepatol Commun       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.